

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>POON CHRISTINE A</u>  (Last) (First) (Middle) <u>777 OLD SAW MILL RIVER ROAD</u>  (Street) <u>TARRYTOWN NY 10591</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>REGENERON PHARMACEUTICALS, INC. [ REGN ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>08/15/2024</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/15/2024		M		10,838	A	\$413.33	13,010	D	
Common Stock	08/15/2024		S		1,012	D	\$1,155.72 <sup>(1)</sup>	11,998	D	
Common Stock	08/15/2024		S		2,368	D	\$1,156.3 <sup>(2)</sup>	9,630	D	
Common Stock	08/15/2024		S		1,560	D	\$1,157.33 <sup>(3)</sup>	8,070	D	
Common Stock	08/15/2024		S		212	D	\$1,158.02 <sup>(4)</sup>	7,858	D	
Common Stock	08/15/2024		S		5,352	D	\$1,159.56 <sup>(5)</sup>	2,506	D	
Common Stock	08/15/2024		S		234	D	\$1,160.45 <sup>(6)</sup>	2,272	D	
Common Stock	08/15/2024		S		100	D	\$1,161.32	2,172	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$413.33	08/15/2024		M		10,838	(7)	01/02/2025	Common Stock	10,838	\$0.0	0	D	

**Explanation of Responses:**

- Represents volume-weighted average price of sales of 1,012 shares of Company stock on August 15, 2024 at prices ranging from \$1,155.38 to \$1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
- Represents volume-weighted average price of sales of 2,368 shares of Company stock on August 15, 2024 at prices ranging from \$1,156.04 to \$1,156.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
- Represents volume-weighted average price of sales of 1,560 shares of Company stock on August 15, 2024 at prices ranging from \$1,157.02 to \$1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
- Represents volume-weighted average price of sales of 212 shares of Company stock on August 15, 2024 at prices ranging from \$1,158.01 to \$1,158.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
- Represents volume-weighted average price of sales of 5,352 shares of Company stock on August 15, 2024 at prices ranging from \$1,159.18 to \$1,159.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
- Represents volume-weighted average price of sales of 234 shares of Company stock on August 15, 2024 at prices ranging from \$1,160.10 to \$1,160.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
- The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

/s/\*\*Christine A. Poon

08/16/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**